201 related articles for article (PubMed ID: 9242514)
1. p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA).
Nataraj AJ; Wolf P; Cerroni L; Ananthaswamy HN
J Invest Dermatol; 1997 Aug; 109(2):238-43. PubMed ID: 9242514
[TBL] [Abstract][Full Text] [Related]
2. High mutation frequency at Ha-ras exons 1-4 in squamous cell carcinomas from PUVA-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Kerl H; Wolf P
Photochem Photobiol; 2001 Aug; 74(2):323-30. PubMed ID: 11547572
[TBL] [Abstract][Full Text] [Related]
3. High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Cerroni L; Kerl H; Wolf P
J Invest Dermatol; 2003 Apr; 120(4):676-82. PubMed ID: 12648234
[TBL] [Abstract][Full Text] [Related]
4. An unexpected spectrum of p53 mutations from squamous cell carcinomas in psoriasis patients treated with PUVA.
Wang XM; McNiff JM; Klump V; Asgari M; Gasparro FP
Photochem Photobiol; 1997 Aug; 66(2):294-9. PubMed ID: 9277151
[TBL] [Abstract][Full Text] [Related]
5. The role of PUVA in the treatment of psoriasis. Photobiology issues related to skin cancer incidence.
Gasparro FP
Am J Clin Dermatol; 2000; 1(6):337-48. PubMed ID: 11702610
[TBL] [Abstract][Full Text] [Related]
6. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis.
Seidl H; Kreimer-Erlacher H; Bäck B; Soyer HP; Höfler G; Kerl H; Wolf P
J Invest Dermatol; 2001 Aug; 117(2):365-70. PubMed ID: 11511317
[TBL] [Abstract][Full Text] [Related]
7. Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy).
Lambertini L; Surin K; Ton TV; Clayton N; Dunnick JK; Kim Y; Hong HH; Devereux TR; Sills RC
Toxicol Pathol; 2005; 33(2):292-9. PubMed ID: 15902973
[TBL] [Abstract][Full Text] [Related]
8. The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients.
Wolf P; Kreimer-Erlacher H; Seidl H; Bäck B; Soyer HP; Kerl H
J Invest Dermatol; 2004 Jan; 122(1):190-200. PubMed ID: 14962108
[TBL] [Abstract][Full Text] [Related]
9. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.
Archier E; Devaux S; Castela E; Gallini A; Aubin F; Le Maître M; Aractingi S; Bachelez H; Cribier B; Joly P; Jullien D; Misery L; Paul C; Ortonne JP; Richard MA
J Eur Acad Dermatol Venereol; 2012 May; 26 Suppl 3():22-31. PubMed ID: 22512677
[TBL] [Abstract][Full Text] [Related]
10. Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers.
Nataraj AJ; Black HS; Ananthaswamy HN
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7961-5. PubMed ID: 8755585
[TBL] [Abstract][Full Text] [Related]
11. Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: the role of molecular epidemiology in minimizing risks.
Gasparro FP; Liao B; Foley PJ; Wang XM; McNiff JM
Environ Mol Mutagen; 1998; 31(2):105-12. PubMed ID: 9544188
[TBL] [Abstract][Full Text] [Related]
12. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization.
Stern RS; Bolshakov S; Nataraj AJ; Ananthaswamy HN
J Invest Dermatol; 2002 Aug; 119(2):522-6. PubMed ID: 12190879
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients.
Monti P; Inga A; Aprile A; Campomenosi P; Menichini P; Ottaggio L; Viaggi S; Ghigliotti G; Abbondandolo A; Fronza G
Mutagenesis; 2000 Mar; 15(2):127-32. PubMed ID: 10719037
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis, PUVA, and skin cancer--molecular epidemiology: the curious question of T-->A transversions.
Peritz AE; Gasparro FP
J Investig Dermatol Symp Proc; 1999 Sep; 4(1):11-6. PubMed ID: 10537001
[TBL] [Abstract][Full Text] [Related]
15. p53 immunoreactivity in cutaneous PUVA tumors is similar to that in other non-melanoma skin neoplasms.
Proby CM; du Peloux Menagé H; McGregor JM; Hobbs C; Norris PG; Smith N; Hawk JL; McKee PH
J Cutan Pathol; 1993 Oct; 20(5):435-41. PubMed ID: 8300928
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in cutaneous lesions induced in the hairless mouse by a solar ultraviolet light simulator.
Queille S; Seite S; Tison S; Medaisko C; Drougard C; Fourtanier A; Sarasin A; Daya-Grosjean L
Mol Carcinog; 1998 Jul; 22(3):167-74. PubMed ID: 9688142
[TBL] [Abstract][Full Text] [Related]
17. Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis.
Grundmann-Kollmann M; Ludwig R; Zollner TM; Ochsendorf F; Thaci D; Boehncke WH; Krutmann J; Kaufmann R; Podda M
J Am Acad Dermatol; 2004 May; 50(5):734-9. PubMed ID: 15097957
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of human papillomavirus type 16-related DNA and absence of detectable p53 gene mutations in widespread cutaneous squamous cell carcinomas after oral psoralen with UV-A treatment.
Rübben A; Baron JM; Grussendorf-Conen EI
Arch Dermatol; 1996 Oct; 132(10):1257-9. PubMed ID: 8859052
[No Abstract] [Full Text] [Related]
19. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients.
Maier H; Schemper M; Ortel B; Binder M; Tanew A; Hönigsmann H
Dermatology; 1996; 193(3):185-91. PubMed ID: 8944338
[TBL] [Abstract][Full Text] [Related]
20. [Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology].
Beani JC; Jeanmougin M
Ann Dermatol Venereol; 2010 Jan; 137(1):21-31. PubMed ID: 20110064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
